---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-008853"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T15:33:15.388139+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma enters $100M ATM equity facility with Cantor Fitzgerald

## Summary
- Agreement with Cantor Fitzgerald to sell up to $100M of common stock via at-the-market offerings.
- Prior ATM agreement with Cowen/ TD Securities terminated upon signing new agreement.
- Sales occur on Nasdaq; Cantor receives up to 3% commission on gross proceeds.
- Shelf registration on Form S-3 filed March 2, 2026, declared effective March 10, 2026.
- Company may suspend or terminate offerings at any time; no obligation to sell.

## SEC filing metadata
- accession: 0001140361-26-008853
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036126008853/0001140361-26-008853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036126008853/ef20067503_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-008853
- JSON: https://secwatch.observer/filing/0001140361-26-008853.json
- Plain text: https://secwatch.observer/filing/0001140361-26-008853.txt

## Key facts
- Material Agreements
  ROCKET PHARMACEUTICALS, INC. terminated Prior Sales Agreement with Cowen and Company, LLC, an affiliate of TD Securities (USA) LLC (effective 2026-03-10).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Cowen and Company, LLC, an affiliate of TD Securities (USA) LLC
  - Effective: 2026-03-10
  source text: Upon entry into the Sales Agreement, the Company terminated its prior “at-the-market” sales agreement with Cowen and Company, LLC, an affiliate of TD Securities (USA) LLC, dated February 28, 2022, (the “Prior Sales Agreement”), as amended by Amendment No. 1 to the Prior Sales Agreement, dated as of September 12, 2023 (“Amendment No. 1”), pursuant to which the Company could offer and sell, from time to time through Cowen and Company, LLC, as its agent, shares of the Company’s common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036126008853/0001140361-26-008853-index.htm
- Material Agreements
  ROCKET PHARMACEUTICALS, INC. entered into Sales Agreement with Cantor Fitzgerald & Co. valued at $100,000,000 (effective 2026-03-10).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: $100,000,000
  - Effective: 2026-03-10
  source text: On March 10, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Sales Agent”), with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share, having an aggregate offering price of up to $100,000,000 (the “Shares”), through the Sales Agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036126008853/0001140361-26-008853-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.